Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer

In this study, we identified a potential inhibitor, namely, C620-0696, by computational docking modeling to target bromodomain. Results of biolayer interferometry revealed that compound C620-0696 exhibited high binding affinity to the BPTF bromodomain. Moreover, C620-0696 was cytotoxic in BPTF with a high expression of non-small-cell lung cancer (NSCLC) cells. It suppressed the expression of the BPTF target gene c-MYC, which is known as an oncogenic transcriptional regulator in various cancers. C620-0696 also partially inhibited the migration and colony formation of NSCLC cells owing to apoptosis induction and cell cycle blockage. Thus, our study presents an effective strategy to target a bromodomain factor-mediated tumorigenesis in cancers with small molecules, supporting further exploration of the use of these inhibitors in oncology.
Source: Frontiers of Medicine - Category: General Medicine Source Type: research

Related Links:

Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4 –12% of EGFR mutations and are generally refractory to the 1st and 2nd generation EGFR tyrosine kinase inhibi...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
This study aimed to evaluate the feasibility and prognostic accuracy of incorporating the number of positive lymph nodes (PLN) into the TNM staging system for non-small cell lung cancer (NSCLC) patients.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
To determine the overall survival (OS) in patients who underwent planned tri-modality therapy (TMT) and those who underwent definitive concurrent chemoradiation (CRT), but later received salvage resection (SR) for stage IIIA (cN2) (AJCC 7th ed.) non-small cell lung cancer (NSCLC).
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: THORACIC – Original Submission Source Type: research
BackgroundThe rationality of selective mediastinal lymph node dissection based on lobe ‐specific metastasis is still controversial. The correlation of lymph node metastasis in lobe‐specific lymphatic drainage regions (LSDRs) and non‐LSDRs has not been widely reported. The purpose of this study was to investigate the variables affecting nodal metastasis in non‐LSDRs and to furt her evaluate the rationality of selective lymphadenectomy in clinical stage IA non‐small cell lung cancer (NSCLC) patients.MethodsThe clinicopathological information of 316 patients with clinical stage IA NSCLC who underwent lobectomy with ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionLncRNANORAD is capable of promoting the proliferation and migration of NSCLC cells, and its mechanism may be that it increases theAKT1 expression by adsorbing miR ‐656‐3p.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
Hille Simon A. Joosse Ronald Simon Markus Tiemann Carsten Bokemeyer Martin Reck Sabine Riethdorf Klaus Pantel Sonja Loges Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in NSCLC is compromised by a low detection rate with the established, Food and Drug Administration (FDA)-approved, EpCAM-based CellSearch® System. We tested an epitope-independent method (ParsortixTM system) and utilized it to assess PD-L1 expression of CTCs from...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Cytotoxic chemotherapy remains an important treatment for patients with non-small cell lung cancer (NSCLC) either alone or in combination with immunotherapy. Studies demonstrating the efficacy of first line treatment with immune checkpoint inhibitors (ICI) alone and in combination with chemotherapy have led to new first-line treatment options for patients with NSCLC [1 –3]. Carboplatin, pembrolizumab and either paclitaxel or nab-paclitaxel are now standard first line options for patients with lung squamous cell carcinoma (LSCC) [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Non-small cell lung cancer (NSCLC) accounts for ˜85% of lung malignancies, which are the leading cause of cancer-related deaths worldwide. In 2011, the National Lung Cancer Screening Trial (NLST) demonstrated in subjects at high-risk that mortality can be reduced 20% by screening with low-dose CT (LDCT) [1]. The U.S. Preventive Services Task For ce recommends LDCT screening in individuals 55-80 years of age with ≥30 pack-year smoking history, current smokers or who have quit within the last 15 years (grade B evidence).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
IntroductionThe aim of this study was to assess the prognoses of patients with non ‐small cell lung cancer (NSCLC) according to the current nodal (N) categories of the tumor, node and metastasis (TNM) classification and the number of involved lymph node stations.MethodsFive hundred and seventy patients with NSCLC underwent surgery from 1 January 2005 to 31 December 2009 and were analysed retrospectively. Postoperative overall survival was analysed according to two nodal classifications: the current N0, N1, N2 and N3 categories and those based on the number of involved nodal stations: N0, N1a (single N1), N1b (multiple N1...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Contributors : Yan Zhang ; Yongyue Wei ; Jingjing Ben ; Chen QiSeries Type : Expression profiling by arrayOrganism : Mus musculusMetastasis is the key determinant of poor prognosis for advanced-stage NSCLC patients. Although an important contributor to metastasis is cross-talk between tumor-associated macrophages (TAMs) and tumor cells, its regulation is not fully understood. Expressed primarily in macrophages, scavenger receptor A1 (SR-A1) has been associated with lung tumorigenesis. Here, the mechanistic basis for the involvement of SR-A1 in lung cancer prognosis was investigated using population genetics, transcriptomic...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | General Medicine | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study